Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Date:9/22/2009

deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 22, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through lice
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
2. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
3. ER Doctor Demonstrates Breast Pump on Live TV with Patented New Freemie Hands-Free System
4. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
5. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
6. Abbott HIV Test Demonstrates Earlier Disease Detection
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
8. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
9. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
10. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
11. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the global pharmaceutical, ... an Investigational New Drug (IND) application for WuXi ... has been accepted for review by the China ... In September 2012, MedImmune, the global biologics research ...
(Date:3/26/2015)... 26, 2015 PRC Clinical, a Silicon-Valley ... several management and executive appointments effective immediately. , Mike ... (CFO) and member of the Board of Directors. Daniel ... and Sue Dowden will assume the position of Senior ... Chief Operations Officer (COO), has been appointed to the ...
(Date:3/26/2015)... CINCINNATI , March 26, 2015 ... NASDAQ: SHPG ) and Cincinnati Children,s Hospital ... collaboration for rare diseases. The goal of the collaboration ... treat rare diseases with high unmet medical need ... Children,s research expertise. As a nationally ranked hospital, ...
(Date:3/26/2015)... "In America," the popular news television program that airs in ... legendary film actor James Earl Jones, has announced that it ... , Botany is commonly described as the scientific study ... bit more complicated than that. Scientists and other professionals study ... the smallest bacteria known to man to the largest trees ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... 18 Danube Pharmaceuticals, Inc., a,privately held biopharmaceutical ... innovative drugs for ophthalmology, is pleased,to announce the ... its Chief,Executive Officer., "I am honored and ... in its history as it advances its lead ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced ... will present at the,Jefferies & Co. 2nd Annual Healthcare ... Wednesday, June 25, 2008., An audio webcast of ... the webcast at: http://www.alexionpharm.com . An archived version ...
... June 18 HemoCue(R) AB, a,global point-of-care diagnostic ... Incorporated (NYSE: DGX ), today announced,that its ... point-of-care,test for screening for, diagnosing and monitoring microalbuminuria ... Food and Drug Administration (FDA). With,the FDA CLIA ...
Cached Biology Technology:Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 2Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 5
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... which has not been seen for nearly a century, has ... be in critical danger of extinction given that the only ... (Spain). A study reveals its characteristics and the reasons ... remains critically endangered. Researchers wants to restore this floral plant ...
... Mo. Plants do not have eyes or legs, yet ... from light. This ability, called phototropism, is controlled by a ... cells. In a paper published in The Plant Cell, ... the elusive role a critical protein plays in this molecular ...
... -- University of New Hampshire scientists have received National ... experiments can be applied to understand the behavior of ... investigate large-scale biological responses to climate and land-use change. ... natural resources and the environment (NREN) and assistant professor ...
Cached Biology News:The Murcian flower has been 'revived' after 100 years 2Protein plays role in helping plants see light 2UNH researchers receive NSF grant to 'scale up' stream ecology 2UNH researchers receive NSF grant to 'scale up' stream ecology 3
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, a ... are arrayed in quadruplicate for high-quality ... specific chip layout guarantee high validity ...
... UNIchip AV-400 contains 400 unique human ... glass slide. The proteins, all extracellular ... classification, are arrayed in quadruplicate for ... a specific chip layout guarantee high ...
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
... Reticulocyte Lysate Systems(a,b,c,d) offer researchers an ... a single-tube, coupled transcription/translation system. The ... process and reduce the time required ... Standard rabbit reticulocyte lysate translations (1) ...
Biology Products: